|
A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types. |
|
|
No Relationships to Disclose |
|
|
Employment - Caris Life Sciences |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Caris Life Sciences |
Travel, Accommodations, Expenses - Caris Life Sciences |
|
|
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies |
|
Consulting or Advisory Role - AstraZeneca; Bayer; Merck; Novartis; Taiho Pharmaceutical |
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Amgen; Merck; Merck KGaA |
|
|
Stock and Other Ownership Interests - Oncoceutics; p53-Therapeutics |
Consulting or Advisory Role - Boehringer Ingelheim |
Research Funding - Bayer; D&D Pharmatech; D&D Pharmatech; D&D Pharmatech; Loxo; Morphotek; Tarmeta Biosciences |
Patents, Royalties, Other Intellectual Property - Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53 |
Other Relationship - Caris Life Sciences |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Novartis; Sermonix Pharmaceuticals |
Research Funding - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; Sermonix Pharmaceuticals |
|
|
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure |
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure |
Research Funding - Novocure |
Travel, Accommodations, Expenses - GlaxoSmithKline |
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan |
|
|
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences |
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences |
Speakers' Bureau - Bayer; Celgene; Incyte; Ipsen; Novartis |
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst) |
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals |
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals |
|
|
Employment - Caris Life Sciences; Indivumed |
Honoraria - Amgen; Bayer/Onyx; Caris Life Sciences; Merck; Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical |
Speakers' Bureau - Amgen; Bayer/Onyx; Merck; Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Caris Life Sciences; ImaginAb |
Speakers' Bureau - Caris Life Sciences |
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Taiho Pharmaceutical; Telix Pharmaceuticals; Xencor |
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget |
|
|
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche |
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche |
Travel, Accommodations, Expenses - Bayer; Merck Serono |
|
|
Leadership - GOG Partners |
Consulting or Advisory Role - Aravive; AstraZeneca; Caris MPI; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; Merck; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Taiho Pharmaceutical |
Speakers' Bureau - Genentech/Roche; Taiho Pharmaceutical |